| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.099 | 0.004 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.005 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.17 | 0.005 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.006 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.006 |